Serum metabolomic signatures associated with growth hormone replacement therapy in children with postoperative craniopharyngioma
Abstract
Growth hormone replacement therapy (GHRT) is commonly used to treat growth hormone deficiency (GHD) after craniopharyngioma (CP) surgery, but its metabolic consequences in pediatric patients remain incompletely characterized. This study aimed to investigate serum metabolomic alterations associated with GHRT in pediatric patients with postoperative childhood-onset CP. We conducted an untargeted serum metabolomics study in 60 pediatric patients with childhood-onset CP following surgery, including 32 patients receiving GHRT and 28 patients not receiving GHRT. Clinical data and biochemical parameters were collected. Serum metabolites were profiled using ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS). Differential metabolite identification, pathway enrichment analysis, and correlation analyses were conducted to characterize GHRT-associated metabolic signatures and their relationships with clinical indicators. Patients receiving GHRT had higher insulin-like growth factor 1 (IGF-1) levels, whereas conventional lipid parameters did not differ significantly between groups. HOMA-IR was higher and QUICKI was lower in the GHRT group. Using stringent criteria of VIP > 1, BH-FDR q < 0.05, and |log₂FC| > 2, 10 key positive-ion metabolites were identified, including phosphatidylcholine, triglycerides, sphingomyelins (SMs), and 3,5-diiodo-L-thyronine (T2). Nine lipid-related metabolites were higher and T2 was lower in the GHRT group. These associations remained significant after adjustment for chronological age and postoperative interval and in sensitivity analyses additionally accounting for sex-steroid replacement. GHRT exposure in children and adolescents with postoperative childhood-onset CP was associated with distinct serum metabolomic signatures, predominantly involving phosphatidylcholine, triglycerides, and SMs. These findings represent exploratory associations and require confirmation in longitudinal studies before treatment-related or clinical implications can be established.
Related
- Primary Amenorrhea Revealing Adamantinomatous Craniopharyngioma Associated With Central Hypogonadotropic Hypogonadism in an Adolescent Girl: A Case Report
- Effect of intraoperative tranexamic acid use on postoperative bleeding in tumor replacement surgery : A retrospective cohort study
- Longitudinal Drain-Fluid Proteomics Reveals Procedure-Specific Signatures of Postoperative Leakage after Pancreatic and Colorectal Surgery
- Metabolomic Signatures of Habitual Physical Activity in Childhood
- Extended endoscopic endonasal resection of a transinfundibular craniopharyngioma with third ventricular extension associated with superficial siderosis: Operative technique and technical nuances.
BibTeX
@article{xu2026serum,
title = {{Serum metabolomic signatures associated with growth hormone replacement therapy in children with postoperative craniopharyngioma}},
author = {Rong Xu and Hanze Du and Liyuan Zhang and Shuaihua Song and Shi Chen and Lian Duan and Huijuan Zhu and Hui Pan},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-74063-9},
url = {https://www.nature.com/articles/s41598-026-74063-9},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Serum metabolomic signatures associated with growth hormone replacement therapy in children with postoperative craniopharyngioma
AU - Rong Xu
AU - Hanze Du
AU - Liyuan Zhang
AU - Shuaihua Song
AU - Shi Chen
AU - Lian Duan
AU - Huijuan Zhu
AU - Hui Pan
PY - 2026
DA - 2026/10/01
JO - Scientific Reports
DO - 10.1038/s41598-026-74063-9
UR - https://www.nature.com/articles/s41598-026-74063-9
AB - Growth hormone replacement therapy (GHRT) is commonly used to treat growth hormone deficiency (GHD) after craniopharyngioma (CP) surgery, but its metabolic consequences in pediatric patients remain incompletely characterized. This study aimed to investigate serum metabolomic alterations associated with GHRT in pediatric patients with postoperative childhood-onset CP. We conducted an untargeted serum metabolomics study in 60 pediatric patients with childhood-onset CP following surgery, including 32 patients receiving GHRT and 28 patients not receiving GHRT. Clinical data and biochemical parameters were collected. Serum metabolites were profiled using ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS). Differential metabolite identification, pathway enrichment analysis, and correlation analyses were conducted to characterize GHRT-associated metabolic signatures and their relationships with clinical indicators. Patients receiving GHRT had higher insulin-like growth factor 1 (IGF-1) levels, whereas conventional lipid parameters did not differ significantly between groups. HOMA-IR was higher and QUICKI was lower in the GHRT group. Using stringent criteria of VIP > 1, BH-FDR q < 0.05, and |log₂FC| > 2, 10 key positive-ion metabolites were identified, including phosphatidylcholine, triglycerides, sphingomyelins (SMs), and 3,5-diiodo-L-thyronine (T2). Nine lipid-related metabolites were higher and T2 was lower in the GHRT group. These associations remained significant after adjustment for chronological age and postoperative interval and in sensitivity analyses additionally accounting for sex-steroid replacement. GHRT exposure in children and adolescents with postoperative childhood-onset CP was associated with distinct serum metabolomic signatures, predominantly involving phosphatidylcholine, triglycerides, and SMs. These findings represent exploratory associations and require confirmation in longitudinal studies before treatment-related or clinical implications can be established.
SN - 2045-2322
ER -